Stock On Watch: PTC Therapeutics, Inc. Increases Again; Strong Momentum for Buyers

Stock On Watch: PTC Therapeutics, Inc. Increases Again; Strong Momentum for Buyers

The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! About 941,485 shares traded hands. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 93.74% since April 14, 2016 and is uptrending. It has outperformed by 89.05% the S&P500.
The move comes after 5 months positive chart setup for the $411.81M company. It was reported on Nov, 16 by Barchart.com. We have $23.60 PT which if reached, will make NASDAQ:PTCT worth $399.46 million more.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. PTC Therapeutics has been the topic of 19 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The rating was initiated by Citigroup with “Buy” on Tuesday, August 25. The firm has “Sector Perform” rating given on Wednesday, February 24 by RBC Capital Markets. As per Wednesday, February 24, the company rating was maintained by Wedbush. The rating was maintained by Oppenheimer on Friday, October 16 with “Outperform”. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Neutral” rating by JP Morgan on Tuesday, February 23. The firm has “Neutral” rating by Credit Suisse given on Tuesday, July 26. The firm has “Buy” rating by Citigroup given on Friday, November 11. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. The rating was upgraded by Credit Suisse on Monday, November 14 to “Outperform”. The firm has “Sector Perform” rating given on Friday, November 11 by RBC Capital Markets.

According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”

Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.40, from 0.83 in 2016Q1. The ratio improved, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
Ubs Asset Management Americas Incorporated accumulated 615,531 shares or 0% of the stock. Blackrock Advsrs Limited Co accumulated 0.01% or 742,711 shares. Parametric Assocs Limited Liability Co has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Federated Pa has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Panagora Asset Inc has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Teachers Retirement Of The State Of Kentucky owns 17,300 shares or 0% of their US portfolio. Nationwide Fund reported 35,300 shares or 0% of all its holdings. Franklin Incorporated holds 0% or 397,800 shares in its portfolio. Tower Rech Capital (Trc) reported 900 shares or 0% of all its holdings. Bank Of Montreal Can last reported 27,009 shares in the company. Comml Bank Of Ny Mellon last reported 0% of its portfolio in the stock. Voya Lc holds 14,593 shares or 0% of its portfolio. Blackrock Mngmt Ltd Co accumulated 183,317 shares or 0% of the stock. Legal General Group Plc has 0% invested in the company for 8,176 shares. Dimensional Fund Ltd Partnership, a Texas-based fund reported 100,783 shares.

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Fool.com which released: “Why PTC Therapeutics, Advanced Micro Devices, and Nordstrom Jumped Today” on November 11, 2016, also 247Wallst.com with their article: “Why PTC Therapeutics Is Soaring” published on November 11, 2016, Fool.com published: “Why PTC Therapeutics Is Rocketing 74% Today” on November 11, 2016. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Fool.com and their article: “Why PTC Therapeutics, Inc. Is Crashing Today” published on October 17, 2016 as well as Prnewswire.com‘s news article titled: “PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial …” with publication date: October 19, 2016.

PTCT Company Profile

PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment